Cargando…

Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?

BACKGROUNDS/AIMS: Gemcitabine is still one of adjuvant options in chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). Integral membrane transporter protein and intracellular enzymes including human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), ribonucleo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Dae Wook, Shin, Eun, Cho, Jai Young, Han, Ho-Seong, Yoon, Yoo-Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Hepato-Biliary-Pancreatic Surgery 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271117/ https://www.ncbi.nlm.nih.gov/pubmed/32457256 http://dx.doi.org/10.14701/ahbps.2020.24.2.127

Ejemplares similares

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?
por: Giacometti, Cinzia, et al.
Publicado: (2023)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease
por: Guitart, Xavier, et al.
Publicado: (2017)

Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): Evidence for allosteric kinetics at acidic pH
por: Tandio, David, et al.
Publicado: (2019)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia
por: Chatzidavid, Sevastianos, et al.
Publicado: (2023)

HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
por: Eltzschig, Holger K., et al.
Publicado: (2005)

Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency
por: Al-Ansari, Mohammad, et al.
Publicado: (2015)

Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1)
por: Boswell-Casteel, Rebba C., et al.
Publicado: (2018)

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine
por: Kalloger, Steve E, et al.
Publicado: (2017)

Equilibrative nucleoside transporter 1 (ENT1) is critical for pollen germination and vegetative growth in Arabidopsis
por: Bernard, Carsten, et al.
Publicado: (2011)

Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice
por: Best, K. Arielle, et al.
Publicado: (2018)

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors
por: Jouan, Elodie, et al.
Publicado: (2021)

Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy
por: Sasaki, H, et al.
Publicado: (2014)

Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development
por: Deniskin, Roman, et al.
Publicado: (2015)

N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function
por: Bicket, Alex, et al.
Publicado: (2016)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
por: Yang, Pei-Ming, et al.
Publicado: (2020)

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
por: Elander, N. O., et al.
Publicado: (2018)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients
por: Cho, Er-Chieh, et al.
Publicado: (2014)

Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1)
por: Logie, Lisa, et al.
Publicado: (2018)

Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling
por: Ruan, Wei, et al.
Publicado: (2023)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells
por: Alarcón, Sebastián, et al.
Publicado: (2020)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
por: Wang, Wei, et al.
Publicado: (2023)

Functional characterization of human equilibrative nucleoside transporter 1
por: Huang, Weiyun, et al.
Publicado: (2016)

Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer
por: Zuo, Zanwen, et al.
Publicado: (2022)

SKM-1细胞地西他滨耐药机制中hENT1功能的研究
Publicado: (2015)

Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022)

Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer
por: Zhou, Dandan, et al.
Publicado: (2023)

DHS (Trans-4,4’-Dihydroxystilbene) Suppresses DNA Replication and Tumor Growth by Inhibiting RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
por: Chen, Chi-Wei, et al.
Publicado: (2018)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

Insight into the nucleoside transport and inhibition of human ENT1
por: Wu, Zhixiang, et al.
Publicado: (2022)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kc52554k77icj2lumk2qj1cbs5